Fiercer battle to be seen in generic antihypertensive drug market

With many global makers' blockbuster products coming off patent, the race for the generic antihypertensive drug market is set to be in full force next year.

The drug recently at the center of attention is the best-selling Almetec Plus, an antihypertensive combination pill that has generated more than 10 billion won in an every-quarter revenue for Daiichi-Sankyo.

So far, Handok Pharm has c...